HighTower Advisors LLC reduced its stake in Doximity, Inc. (NASDAQ:DOCS – Free Report) by 61.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 25,054 shares of the company’s stock after selling 39,677 shares during the period. HighTower Advisors LLC’s holdings in Doximity were worth $1,091,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also modified their holdings of DOCS. Farther Finance Advisors LLC lifted its holdings in Doximity by 324.2% during the 3rd quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock valued at $34,000 after purchasing an additional 603 shares during the last quarter. Blue Trust Inc. increased its holdings in shares of Doximity by 621.4% during the second quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock worth $37,000 after buying an additional 1,193 shares in the last quarter. Quarry LP raised its stake in shares of Doximity by 101.2% in the second quarter. Quarry LP now owns 1,616 shares of the company’s stock valued at $45,000 after acquiring an additional 131,253 shares during the last quarter. First Horizon Advisors Inc. raised its stake in shares of Doximity by 80.0% in the second quarter. First Horizon Advisors Inc. now owns 1,710 shares of the company’s stock valued at $48,000 after acquiring an additional 760 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Doximity by 40.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,439 shares of the company’s stock worth $63,000 after acquiring an additional 412 shares in the last quarter. 87.19% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research firms recently weighed in on DOCS. The Goldman Sachs Group assumed coverage on Doximity in a report on Friday, November 15th. They set a “neutral” rating and a $58.00 price target for the company. Baird R W raised Doximity to a “strong-buy” rating in a report on Tuesday, September 17th. Evercore ISI increased their price objective on shares of Doximity from $34.00 to $45.00 and gave the stock an “in-line” rating in a report on Tuesday, October 8th. Raymond James reaffirmed an “outperform” rating and issued a $65.00 target price (up from $37.00) on shares of Doximity in a research note on Friday, November 8th. Finally, Barclays increased their price target on shares of Doximity from $52.00 to $75.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Twelve investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $52.44.
Doximity Trading Down 1.1 %
NASDAQ DOCS opened at $52.71 on Wednesday. Doximity, Inc. has a 12 month low of $22.96 and a 12 month high of $61.75. The stock has a 50-day simple moving average of $48.41 and a 200 day simple moving average of $38.36. The company has a market capitalization of $9.84 billion, a PE ratio of 60.58, a P/E/G ratio of 4.16 and a beta of 1.40.
Doximity Company Profile
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Featured Stories
- Five stocks we like better than Doximity
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- Why Invest in High-Yield Dividend Stocks?
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Salesforce’s Clear Path to $400 and Beyond
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.